DMHCA

DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects and can be used for the research of cholesterol homeostasis diabetes[1].

Signaling Pathways >> Metabolic Enzyme/Protease >> LXR

Research Areas >> Metabolic Disease

IC50: LXR[1]

In ex vivo treatment of diabetic CD34+ cells, DMHCA (10 µM; 16-18 hours) restores the fluidity of the membranes to baseline nondiabetic levels[1]. DMHCA restores the levels of BM-derived TNF-α and IL-3 to baseline and significantly reduces CCL-2 production by >50% in the BM supernatants and the systemic circulation compares to the control mice. DMHCA also increases the number of CACs in the BM and peripheral circulation and upregulates the egression of vascular reparative cells into the peripheral circulation[1]. In the PAGA analysis, DMHCA treatment enhances the overall production and robustness of erythrocyte progenitors. DMHCA enhances flux down the erythrocyte progenitor lineage. It also DMHCA increase in erythrocyte progenitor density in BM cells. DMHCA not only expands the proportion of erythrocyte progenitors but also increases the expression of the hemoglobin beta adult chain (HBB-BT)[1].

DMHCA (oral administration; 6 months; chow 8mg/kg body weight /day) restores cholesterol homeostasis in diabetic retina. It significantly increases endogenous LXR ligands, desmosterol, and total oxysterols in the diabetic retina[1].

[1]. Cristiano P Vieira, et al. Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes. JCI Insight. 2020 Jul 9;5(13):e137230.